SEC Form 4 · accession 0000899243-19-007113
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael A. Panzara
Officer — Franchise Lead, Neurology
Period of report
Mar 7, 2019
Accepted (ET)
Mar 11, 2019 · 7:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Mar 7, 2019 | A | 15,000 | $0.00 | A | 52,388 | D | |
| Ordinary Shares | Mar 11, 2019 | S | 7,000 | $48.00 | D | 45,388 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023.
- F2Consists of sale of RSUs effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2018.